Evidence network for deaths_(OS)

1EAGLE (D vs ICC), 20191CheckMate 141, 20162KEYNOTE-040 (all population), 2018 KEYNOTE-040 (CPS >1), 20181EAGLE (DT vs ICC), 20191CONDOR (DT vs D ; PDL1 TC<25%), 20191CONDOR (DT vs T ; PDL1 TC<25%), 2019durvalumab alone vs. durvalumab plus tremelimumab 0.90 [0.72; 1.13]0.90 [0.72;1.13]durvalumab alone vs. durvalumab plus tremelimumab 0.90 [0.72; 1.13]durvalumab alone vs. nivolumab alone 1.30 [0.90; 1.87]1.30 [0.90;1.87]durvalumab alone vs. nivolumab alone 1.30 [0.90; 1.87]durvalumab alone vs. pembrolizumab alone 1.18 [0.93; 1.50]1.18 [0.93;1.50]durvalumab alone vs. pembrolizumab alone 1.18 [0.93; 1.50]durvalumab alone vs. Standard of Care (SoC) 0.91 [0.76; 1.09]0.91 [0.76;1.09]durvalumab alone vs. Standard of Care (SoC) 0.91 [0.76; 1.09]durvalumab alone vs. tremelimumab durvalumab alone better 0.65 [0.43; 0.99]0.65 [0.43;0.99]durvalumab alone vs. tremelimumab durvalumab alone better 0.65 [0.43; 0.99]durvalumab plus tremelimumab vs. durvalumab alone 1.11 [0.88; 1.38]1.11 [0.88;1.38]durvalumab plus tremelimumab vs. durvalumab alone 1.11 [0.88; 1.38]durvalumab plus tremelimumab vs. nivolumab alone nivolumab alone better 1.44 [1.00; 2.07]1.44 [1.00;2.07]durvalumab plus tremelimumab vs. nivolumab alone nivolumab alone better 1.44 [1.00; 2.07]durvalumab plus tremelimumab vs. pembrolizumab alone pembrolizumab alone better 1.30 [1.03; 1.65]1.30 [1.03;1.65]durvalumab plus tremelimumab vs. pembrolizumab alone pembrolizumab alone better 1.30 [1.03; 1.65]durvalumab plus tremelimumab vs. Standard of Care (SoC) 1.01 [0.84; 1.20]1.01 [0.84;1.20]durvalumab plus tremelimumab vs. Standard of Care (SoC) 1.01 [0.84; 1.20]durvalumab plus tremelimumab vs. tremelimumab 0.72 [0.51; 1.02]0.72 [0.51;1.02]durvalumab plus tremelimumab vs. tremelimumab 0.72 [0.51; 1.02]nivolumab alone vs. durvalumab alone 0.77 [0.53; 1.11]0.77 [0.53;1.11]nivolumab alone vs. durvalumab alone 0.77 [0.53; 1.11]nivolumab alone vs. durvalumab plus tremelimumab nivolumab alone better 0.70 [0.48; 1.00]0.70 [0.48;1.00]nivolumab alone vs. durvalumab plus tremelimumab nivolumab alone better 0.70 [0.48; 1.00]nivolumab alone vs. pembrolizumab alone 0.90 [0.64; 1.29]0.90 [0.64;1.29]nivolumab alone vs. pembrolizumab alone 0.90 [0.64; 1.29]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.70 [0.51; 0.96]0.70 [0.51;0.96]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.70 [0.51; 0.96]nivolumab alone vs. tremelimumab nivolumab alone better 0.50 [0.30; 0.83]0.50 [0.30;0.83]nivolumab alone vs. tremelimumab nivolumab alone better 0.50 [0.30; 0.83]pembrolizumab alone vs. durvalumab alone 0.85 [0.67; 1.08]0.85 [0.67;1.08]pembrolizumab alone vs. durvalumab alone 0.85 [0.67; 1.08]pembrolizumab alone vs. durvalumab plus tremelimumab pembrolizumab alone better 0.77 [0.61; 0.97]0.77 [0.61;0.97]pembrolizumab alone vs. durvalumab plus tremelimumab pembrolizumab alone better 0.77 [0.61; 0.97]pembrolizumab alone vs. nivolumab alone 1.11 [0.78; 1.57]1.11 [0.78;1.57]pembrolizumab alone vs. nivolumab alone 1.11 [0.78; 1.57]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.77 [0.66; 0.90]0.77 [0.66;0.90]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.77 [0.66; 0.90]pembrolizumab alone vs. tremelimumab pembrolizumab alone better 0.55 [0.36; 0.84]0.55 [0.36;0.84]pembrolizumab alone vs. tremelimumab pembrolizumab alone better 0.55 [0.36; 0.84]Standard of Care (SoC) vs. durvalumab alone 1.10 [0.92; 1.32]1.10 [0.92;1.32]Standard of Care (SoC) vs. durvalumab alone 1.10 [0.92; 1.32]Standard of Care (SoC) vs. durvalumab plus tremelimumab 0.99 [0.83; 1.19]0.99 [0.83;1.19]Standard of Care (SoC) vs. durvalumab plus tremelimumab 0.99 [0.83; 1.19]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.43 [1.04; 1.96]1.43 [1.04;1.96]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.43 [1.04; 1.96]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.29 [1.11; 1.51]1.29 [1.11;1.51]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.29 [1.11; 1.51]Standard of Care (SoC) vs. tremelimumab 0.72 [0.48; 1.06]0.72 [0.48;1.06]Standard of Care (SoC) vs. tremelimumab 0.72 [0.48; 1.06]tremelimumab vs. durvalumab alone durvalumab alone better 1.54 [1.01; 2.33]1.54 [1.01;2.33]tremelimumab vs. durvalumab alone durvalumab alone better 1.54 [1.01; 2.33]tremelimumab vs. durvalumab plus tremelimumab 1.39 [0.98; 1.97]1.39 [0.98;1.97]tremelimumab vs. durvalumab plus tremelimumab 1.39 [0.98; 1.97]tremelimumab vs. nivolumab alone nivolumab alone better 2.00 [1.21; 3.31]2.00 [1.21;3.31]tremelimumab vs. nivolumab alone nivolumab alone better 2.00 [1.21; 3.31]tremelimumab vs. pembrolizumab alone pembrolizumab alone better 1.81 [1.18; 2.76]1.81 [1.18;2.76]tremelimumab vs. pembrolizumab alone pembrolizumab alone better 1.81 [1.18; 2.76]tremelimumab vs. Standard of Care (SoC) 1.40 [0.94; 2.07]1.40 [0.94;2.07]tremelimumab vs. Standard of Care (SoC) 1.40 [0.94; 2.07]Standard of Care (SoC)durvalumab alonetremelimumabnivolumab alonepembrolizumab alonedurvalumab plus tremelimumabdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)durvalumab alonetremelimumabnivolumab alonepembrolizumab alonedurvalumab plus tremelimumab
Standard of Care (SoC)---1.10
0.92; 1.32		0.72
0.48; 1.06		1.43
1.04; 1.96		1.29
1.11; 1.51		0.99
0.83; 1.19
durvalumab alone0.91
0.76; 1.09		---0.65
0.43; 0.99		1.30
0.90; 1.87		1.18
0.93; 1.50		0.90
0.72; 1.13
tremelimumab1.40
0.94; 2.07		1.54
1.01; 2.33		---2.00
1.21; 3.31		1.81
1.18; 2.76		1.39
0.98; 1.97
nivolumab alone0.70
0.51; 0.96		0.77
0.53; 1.11		0.50
0.30; 0.83		---0.90
0.64; 1.29		0.70
0.48; 1.00
pembrolizumab alone0.77
0.66; 0.90		0.85
0.67; 1.08		0.55
0.36; 0.84		1.11
0.78; 1.57		---0.77
0.61; 0.97
durvalumab plus tremelimumab1.01
0.84; 1.20		1.11
0.88; 1.38		0.72
0.51; 1.02		1.44
1.00; 2.07		1.30
1.03; 1.65		---

pathologies: 278,101,192,114 - treatments: 634,861 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons